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The emergence of a neoplasm results from accumulated mutations
of genes that encode factors involved in signal transduction, cell
proliferation and other cellular processes. Protein kinases are key
intracellular transducers of mitogenic signals that trigger gene
expression and cellular proliferation (Carpenter et al, 1990). It is
thought that a variety of proliferative disorders, such as cancer,
might reflect abnormalities in signal transduction (Levitzki, 1996).
ERK is a component of one of the mammalian mitogen-acti-
vated protein kinase (MAPK) cascades (reviewed in Lewis et al,
1998). The MAPK pathway is triggered by a surface receptor
through the action of the guanosine 5¢-triphosphate(GTP)-binding
protein p21 Ras. Activated Ras binds and activates the c-Raf
protein kinase that, in turn, phosphorylates and activates MAPK
kinase (MEK). MEK then phosphorylates and activates MAPK.
The rapid activation of the MAPK cascade and the phosphoryla-
tion of its targets plays a pivotal role in the signal transduction
pathway activating quiescent cells to re-enter the cell cycle at G1.
The phosphorylation of the 40S ribosomal proteins S6 is
another early event associated with mitogenic response (Thomas
et al, 1979; Decker, 1981). Its phosphorylation is mediated by
70 kDa and 90 kDa ribosomal S6 kinases denoted p70S6k and
p90rsk respectively (Banerjee et al, 1990; Kozma et al, 1990;
Moller et al, 1994). Both p70S6k and p90rsk are active in vivo
towards specific five-serine residue of the S6 proteins (Pullen and
Thomas, 1997). While p70S6k is relatively specific for phospho-
rylation of ribosomal S6 protein, the p90rsk has a wider range of
substrates including proteins that contain consensus phosphoryla-
tion site, R-X-X-S (Sturgil and Wu, 1991). Although both
enzymes share amino acids sequence similarity, they are regulated
by different kinase cascades. Whereas p90rsk is activated by the
Ras-dependent MAPK pathway (Marshall, 1994), activation of
p70S6k requires serial multisite phosphorylations by proline-
directed kinases (such as MAPK), an unidentified PtdIns(3,4,5)-
P3-dependent kinase, and constitutively active PDK1 (Downward,
1998).
Stimulation of cells with epidermal growth factor (EGF) can
result in cellular proliferation, morphogenesis and chemotaxis.
EGF is a potent mitogen for hepatocytes in vitro (McGowan et al,
1981). It is also produced by the liver during the immediate–early
phase of the liver growth (Mullhaupt et al, 1994) and functions in
mice as a mitogen during liver regeneration (Fausto et al, 1995).
Recently, we have shown that cytoplasmic and nuclear MAP,
p70S6 and p90rs kinases are activated after intraperitoneal injec-
tion of EGF in mouse liver (Ostrowski et al, 2000) that may reflect
a role of kinase cascades in liver regeneration and repair. Activator
protein 1 (AP-1) transcription factor, a dimeric complex composed
of the Fos and Jun families, regulates various aspects of growth
and differentiation (Lee et al, 1987; Nadori et al, 1997). AP-1
DNA-binding activity was also stimulated by EGF.
ODC activity is a key regulatory enzyme in growth processes
(Pegg, 1986). Sustained high level of ODC activity is thought to
play a role in tumorigenesis. For example, increased expression of
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tocarcinogenesis (Huber et al, 1989) and in human hepatocellular
carcinoma (Tamori et al, 1994). ODC activity was also correlated
with growth rate in a panel of hepatoma cell lines (Williams-
Ashman et al, 1972).
To gain more insight into the role of MAP, p70S6 and p90rs
kinases, AP-1 and ODC in malignancies we examined the activity
of these factors in spontaneous hepatocellular neoplasms in CBA-
T6 mice and in liver-implanted L1 sarcoma tumours in BALB/c
mice. We found that cytosolic and nuclear activities of these
enzymes were higher in the tumours compared to the surrounding
normal tissue. Surprisingly, the kinase activities in normal tissue
of livers harbouring tumours were higher compared to the livers
from normal control mice without a neoplasm. ODC activity
closely followed the same pattern. Systemic administration of
EGF into mice stimulated activity of these enzymes in normal
liver tissue and tumours to the same level. AP-1 DNA-binding
activity was increased in nuclear extracts from the neoplasms but
was not detected in the adjacent hepatic tissue.
MATERIALS AND METHODS
Animals and treatment protocol
Mice housed at Cancer Center, Warsaw, breeding facilities were
maintained under constant room temperature with a 12–12-h
light–dark cycle and permitted free access to water and to standard
food pellets. The animals received humane care in compliance
with the regulations of Cancer Center. We used CBA-T6/W mice
which had developed spontaneous hepatocellular neoplasms.
Control CBA-T6/W mice were 24 months of age.
Experiments also utilized BALB/c mice with liver-implanted
L1 sarcoma tumours. L1 sarcoma cell line was propagated under
standard conditions in modified Eagle’s medium (MEM) supple-
mented with 10% fetal calf serum (FCS) and antibiotics (Janik 
et al, 1981). Two-month-old BALB/c mice were anaesthetized
with ether for laparotomy and 105 viable L1 cells, suspended in
0.05 ml of phosphate-buffered saline (PBS) were injected under
the capsule of the left lateral lobe of the liver. There was no peri-
operative mortality. Three weeks later, animals with implanted
hepatic tumours and those sham-operated were used in these
studies.
Ten minutes after intraperitoneal injection (10 ml g–1 of body
weight) of 0.9% saline or 0.9% saline containing EGF (1 mg ml–1),
mice anaesthetized with ether were sacrificed, the livers were
rapidly resected and classified by gross examination into tumour
and hepatic tissue. Two portions of each specimen were frozen in
liquid nitrogen and stored in – 80°C until use. The remaining
portions were fixed in formalin and embedded in paraffin for
histological examination.
Cytoplasmic and nuclear extracts were prepared by a modified
method of Dignam et al (1983) as described previously (Ostrowski
et al, 1991) using frozen tissues which were pulverized under
liquid nitrogen with a Mikro-Dismembrator II (B.Braun). In addi-
tion to dithiothreitol (DTT) (0.5 mM), phenylmethylsulphonyl
fluoride (PMSF) (0.5 mM) and leupeptin (10 mg ml–1), the
lysis, extraction and dilution buffers contained the following
phosphatase inhibitors: 30 mM p-nitrophenyl phosphate (pNPP),
10 mM sodium fluoride (NaF), 0.1 mM sodium orthovanadate
(Na3VO4), 0.1 mM sodium molibdate (Na2MoO4) and 10 mM
b-glycerophosphate.
Separation of the nuclear fraction from the cytosol was moni-
tored with the cytosolic enzyme marker lactic dehydrogenase and
the purity of nuclear extracts was greater than 92%.
The protein concentration was measured using MicroBCA
protein assay (Pierce Chemical).
Assay for p42–p44 MAPK, p706Sk and p90rsk activities
Immunocomplex kinase assays were performed as described
previously (Ostrowski et al, 1998). Cytoplasmic and nuclear
extracts containing 300 mg of total protein were immunoprecipi-
tated with 5 mg of either anti-ERK1/anti-ERK2, anti-p70S6, 
or anti-p90rsk polyclonal antibodies (Santa Cruz Biotechnology) 
in immunoprecipitation buffer (150 mM sodium chloride (NaCl),
50 mM Tris–HCl, pH 7.5, 5 mM EGTA, 1% Triton X-100, 0.5%
NP-40, 25 mM pNPP, 5 mM benzamidine, 1 mM PMSF, 20 mM
NaF, 0.2 mM Na3VO4, 10 mg ml–1 leupeptin) for 2 h at 4°C. Then
25 ml of protein A/G beads, which had been preincubated with
immunoprecipitation buffer, were added and the samples were
incubated overnight at 4°C on the rotator.
For MAPK immunocomplex assays, the beads were washed
twice with immunoprecipitation buffer and twice with MAPK
assay buffer (25 mM HEPES–NaOH (sodium hydroxide), pH 7.5,
10 mM b-glycerophosphate, 20 mM magnesium chloride (MgCl2),
2m M manganese chloride (MnCl2), 0.1% Triton X-100, 0.1 mM
DTT, 0.1 mM Na3VO4). Next, beads were mixed with 40 ml of
MAPK assay buffer containing 20 mM ATP – 0.3 mCi [g32P]ATP,
2 mg protein kinase A (PKA) inhibitor, 2 mg PKC inhibitor, and
15 mg MBP peptide (APRTPGGRR). Phosphorylation reactions
were carried out for 10 min at 30°C.
For p70S6k and p90rsk immunocomplex assays, the beads were
washed twice with immunoprecipitation buffer and twice with
p70/p90 assay buffer (25 mM Tris–HCl, pH 7.5, 10 mM b-glycero-
phosphate, 10 mM MgCl2, 0.1 mM DTT, 0.1 mM Na3VO4). Next,
beads were mixed with 40 ml of p70/p90 kinase assay buffer
containing 20 mM ATP – 0.3 mCi [g32P]ATP, 2 mg PKA inhibitor, 
2 mg PKC inhibitor and 15 mg S6 peptide (RRRLSSLRA).
Phosphorylation reactions were carried out for 15 min at 30°C.
The reactions were terminated by adding 10 ml of 20%
trichloroacetic acid (TCA). After centrifugation, the supernatants
were spotted onto Whatman P-81 papers. The papers were washed
several times in 0.5% phosphoric acid, rinsed with acetone, dried
and counted for the radioactivity. Reaction blanks were prepared
by using reaction mixture without peptide substrate. All assays
were done in triplicates. The results were expressed in c.p.m. as
radioactivity incorporated into MBP or S6 peptide.
Assay of ornithine decarboxylase activity
ODC activity was assayed using a method previously described
(Ostrowski et al, 1993). Frozen specimens were homogenized
using Polytron PT1200 (Kinematica AG) in 300 ml of buffer
containing 50 mM HEPES–NaOH (pH = 7.5), 2.5 mM DTT,
0.25 mM pyridoxal 5-phosphate and 0.1 mM EDTA. The reaction
mixture consisted of 20 ml of homogenate’s supernatant, 0.25 mM
pyridoxal 5-phosphate, 2.5 mM DTT, 50 mM HEPES–NaOH
(pH = 7.5), 0.1 mM EDTA with 0.2 mCi of L-[14C]-ornithine
hydrochloride (Amersham International) in a total volume of
40 ml. The reaction tube was sealed with plastic pipet tip
containing a 0.5 cm ´ 4.0 cm piece of Whatman No. 1 filter paper
soaked with 40 ml of b-phenylethylamine. Tubes were incubated
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200 ml of 2 M citric acid. After a further 60 min of incubation, the
filter paper was removed, placed in 10 ml of scintillation liquid
and counted in a scintillation counter. Results were expressed as
pmol of 14CO2 released per h mg–1 of protein. All assays were
performed in triplicate.
Electrophoresis and immunoblotting
Equal amounts of sample protein (100 mg) were boiled in 2 ´
loading buffer (125 mM Tris–HCl, pH 6.8, 4% sodium dodecyl
sulphate (SDS), 20% glycerol and 10% b-mercaptoethanol) (1:1,
vol/vol) for 5 min. Proteins were separated by 10% or 12% SDS
polyacrylamide gel electrophoresis (SDS-PAGE). After bathing
the gel in transfer buffer (192 mM glycine, 25 mM Tris, 20%
methanol, 0.005% SDS) for 30 min, proteins were electroblotted
to polyvinyl difluoride (PVDF) membrane in transfer buffer. The
membrane was blocked with 5% non-fat dry milk in TBST buffer
(Tris-buffered saline containing 0.05% Tween-20) for 1 h at room
temperature. Then, the membranes were probed for 1 h at room
temperature with polyclonal anti-ERK-1/ERK-2, anti-p70S6k,
anti-p90rsk, anti-EGF-receptor, anti-c-Jun, anti-JunB, anti-JunD,
anti-c-Fos, anti-FosB, anti-Fra1, or anti-Fra2 antibodies (Santa-
Cruz Biotechnology) diluted in 5% non-fat dry milk/TBST buffer.
After washing, the membranes were incubated for 60 min at room
temperature with secondary antibodies conjugated with alkaline
phosphatase or horseradish peroxidase, and immunoreactions were
detected using BCIP/NBT phosphatase substrate or enhanced
chemiluminescence (ECL) Western blotting detection system.
EGF receptor tyrosine phosphorylation
Cytoplasmic extracts containing 1 mg of total protein were
immunoprecipitated with 10 mg of EGF receptor (EGFR) poly-
clonal antibodies (Santa-Cruz Biotechnology) in immunoprecipi-
tation buffer for 2 h at 4°C. Then 25 ml of protein A/G beads,
which had been preincubated with immunoprecipitation buffer,
were added and the samples were incubated for 2 h at 4°C on the
rotator. After centrifugation beads were washed four times with
1 ml of immunoprecipitation buffer and proteins were eluted by
boiling in loading buffer. Eluted proteins were resolved on SDS-
PAGE, and after electrotransfer, Western blotting was carried out
with either an anti-phosphotyrosine or anti-EGFR antibodies.
Electrophoretic mobility shift assay
The double-stranded oligonucleotide probe (sense strand, 5¢-
CTAGTGATGAGTCAGCCGGATC-3¢) was end-labelled using
[g32P]ATP and T4 polynucleotide kinase. Twenty micrograms of
nuclear proteins were incubated in binding buffer (20 mM
HEPES–NaOH, pH 7.9, 20% glycerol, 100 mM potassium chloride
(KCl), 0.5 mM EDTA, 0.25% NP-40, 2 mM DTT, 0.1% PMSF)
containing 2 mg poly(dI-dC), and 32P-labelled probe for 30 min at
room temperature. The reactions were loaded onto a 6% native
polyacrylamide gel. The gels were dried and autoradiographed.
Statistical analysis
Results are presented as means ± standard deviation (s.d.).
Significant difference between mean values was assessed by
means of analysis of variance (ANOVA). P-values for differences
from control results were calculated using NIR test. Means were
considered to be different if P < 0.05.
RESULTS
Spontaneous hepatocellular neoplasms are among the most
common murine tumours. The intracellular processes responsible
for these malignancies are poorly defined. To better understand
these mechanisms we examined the activities of several kinases
and other factors in 2-year-old CBA-T6 mice with spontaneous
liver tumours histologically classified (Frith et al, 1994) as hepato-
cellular adenoma and hepatocellular carcinoma. We also studied
2-month-old BALB/c mice with transplantable L1 sarcoma
implanted into the liver.
MAPK activities in hepatic tumours, livers harbouring
tumours and livers from control mice after
intraperitoneal injection of either saline or EGF
Animals were treated with intraperitoneal injection of either saline
or EGF. After ether anaesthesia livers were harvested, the tissues
were histologically typed and frozen. Cytoplasmic and nuclear
extract from frozen tissue were prepared and MAPK activities
were measured by immunocomplex kinase assay. Results from
these series of experiments are shown in Figure 1. In saline-treated
mice (basal) both nuclear and cytoplasmic MAPK activities in
liver adenomas and carcinomas were higher than the activities in
the uninvolved part of the livers that harboured these tumours
(cytoplasmic extracts (CE): adenoma vs adjacent liver P < 0.01;
carcinoma vs adjacent liver P < 0.05), (nuclear extracts (NE):
adenoma vs adjacent liver P < 0.01; carcinoma vs adjacent liver
P < 0.05) or the livers from control animals (CE: adenoma vs
control liver P < 0.01; carcinoma vs control liver P < 0.05),
(NE: adenoma vs control liver P < 0.01; carcinoma vs control liver
P < 0.05). Unexpectedly, these results also revealed that the
MAPK activities are not only increased in the liver tumours but
also in the surrounding histologically normal hepatic tissue
(CE: liver harbouring adenoma vs control liver P < 0.05; liver
harbouring carcinoma vs control liver P < 0.01), (NE: liver
harbouring adenoma vs control liver P < 0.01; liver harbouring
carcinoma vs control liver P < 0.01). Intraperitoneal injection of
EGF not only increased cytoplasmic and nuclear MAPK activities
in the livers of control animals and in the normal part of the livers
of animals with the tumours but also in the tumours themselves
(Figure 1). In fact, while there were demonstrable differences in
the basal (saline-treated animals) MAPK activities between
tumours and the normal tissues, the differences in the MAPK
activities between tumours and the adjacent hepatic tissues from
EGF-treated animals were not significant (CE: adenoma vs adja-
cent liver P = n.s.; carcinoma vs adjacent liver P < 0.05),
(NE: adenoma vs adjacent liver P = n.s.; carcinoma vs adjacent
liver P = n.s.), (CE: adenoma vs control liver P = n.s.; carcinoma
vs control liver P < 0.05), (NE: adenoma vs control liver P = n.s.;
carcinoma vs control liver P = n.s.), (CE: liver harbouring
adenoma vs control liver P = n.s.; liver harbouring carcinoma vs
control liver P = n.s.), (NE: liver harbouring adenoma vs control
liver P = n.s.; liver harbouring carcinoma vs control liver P = n.s.).
As in the case of spontaneous hepatic tumours, the nuclear and
cytoplasmic basal MAPK activities in the implanted liver
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in the normal tissue of the liver harbouring these tumour (Figure 1)
(CE: sarcoma vs adjacent liver P < 0.05), (NE: sarcoma vs adja-
cent liver P < 0.05). Also, the MAPK activities in the normal
tissues from livers harbouring these sarcomas were several-fold
higher than the activities of MAPK in the livers of sham-operated
BALB/c mice (CE: liver harbouring sarcoma vs control liver
P < 0.01), (NE: liver harbouring sarcoma vs control liver
P < 0.01). After treatment with EGF, cytoplasmic and nuclear
MAPK activities increased several-fold, and in all the tissues
MAPK activities reached the same high levels (CE: sarcoma vs
adjacent liver P = n.s.), (NE: sarcoma vs adjacent liver P = n.s.),
(CE: liver harbouring sarcoma vs control liver P = n.s.), (NE: liver
harbouring sarcoma vs control liver P = n.s.).
p70S6k activities in hepatic tumours, livers harbouring
tumours and livers from control mice after
intraperitoneal injection of either saline or EGF
Immunocomplex kinase assays were carried out to assess the
activities of p70S6k (Figure 2) in the same tissues that were used
to measure MAPK activities (Figure 1). As in the case of MAPK,
the basal activities of p70S6k in spontaneous hepatic tumours
were higher than those measured in the adjacent normal liver
1044 J Ostrowski et al
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Figure 1 MAPK activities in hepatic spontaneous tumours, livers harbouring tumours and livers from control CBA-T6/W mice (A, B) and in hepatic-implanted
sarcomas, livers harbouring tumours and livers from control BALB/c mice (C, D) after intraperitoneal injection of either saline or EGF. CBT-T6/W mice with
spontaneous hepatocellular neoplasm and BALB/c mice with liver implanted L1 sarcoma tumours as well as control 24-month-old CBA-T6/W or sham-operated
BALB/c mice were used. Ten minutes after intraperitoneal injection of either saline or EGF (10 mg g–1 of body weight), animals were anaesthetized, livers were
harvested, classified into tumour or normal hepatic tissue and were frozen in liquid nitrogen until use. Cytosolic (A, C) and nuclear (B, D) extracts were prepared
and immunocomplex kinase assays were performed (see Methods). Results are shown for MAPK activities in livers from normal animals (control), in the pair of
adenomas (adenoma) and the harbouring livers (adjacent tissue), in the pair of carcinomas (carcinoma) and the harbouring livers (adjacent tissue), and in the
pair of sarcomas (sarcoma) and the harbouring livers (adjacent tissue). Results represent means ± s.d. of six pairs of control CBA-T6/W and six pairs of control
BALB/c animals, seven pairs of animals with hepatocellular adenomas, four pairs of animals with hepatocellular carcinomas and ten pairs of animals with
implanted sarcomas.tissue or livers from control animals (CE: adenoma vs adjacent
liver P < 0.05; carcinoma vs adjacent liver P < 0.05), (NE:
adenoma vs adjacent liver P < 0.05; carcinoma vs adjacent liver
P < 0.05), (CE: adenoma vs control liver P < 0.05; carcinoma vs
control liver P < 0.01), (NE: adenoma vs control liver P < 0.05;
carcinoma vs control liver P < 0.01). Also, the p70S6k activities in
the livers harbouring the neoplasms were higher that the activity of
this enzyme measured in the livers of control animals without
tumour (CE: liver harbouring adenoma vs control liver P < 0.05;
liver harbouring carcinoma vs control liver P < 0.01), (NE: liver
harbouring adenoma vs control liver P < 0.05; liver harbouring
carcinoma vs control liver P < 0.01). EGF treatment stimulated
p70S6k activities in tumours and normal tissues to the same level
but the degree of the fold-increase was not as large as that seen
with the EGF-inducible MAPK activity (compare Figures 1 and 2)
(CE: adenoma vs adjacent liver P = n.s.; carcinoma vs adjacent
liver P = n.s.), (NE: adenoma vs adjacent liver P = n.s.; carcinoma
vs adjacent liver P = n.s.), (CE: adenoma vs control liver P = n.s.;
carcinoma vs control liver P = n.s.), (NE: adenoma vs control liver
P = n.s.; carcinoma vs control liver P = n.s.), (CE: liver harbouring
adenoma vs control liver P = n.s.; liver harbouring carcinoma vs
control liver P = n.s.), (NE: liver harbouring adenoma vs control
liver P = n.s.; liver harbouring carcinoma vs control liver P = n.s.).
As in the case of spontaneous hepatic tumours, the nuclear and
cytoplasmic p70S6k activities in the implanted liver sarcomas in
saline-treated BALB/c mice were higher than the p70S6k activities
in the normal tissue of the livers with implanted tumours (Figure
2) (CE: sarcoma vs adjacent liver P < 0.05), (NE: sarcoma vs adja-
cent liver P < 0.05). Also, the p70S6k activities in the normal
tissues from livers harbouring the sarcomas were significantly
higher than the activities of this enzyme in the livers of sham-
operated BALB/c mice (CE: liver harbouring sarcoma vs control
liver P < 0.05), (NE: liver harbouring sarcoma vs control liver
P < 0.05). After treatment with EGF, cytoplasmic and nuclear
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Figure 2 p70S6k activities in hepatic spontaneous tumours, livers harbouring tumours and livers from control CBA-T6/W mice (A, B) and in hepatic-implanted
sarcomas, livers harbouring tumours and livers from control BALB/c mice (C, D) after intraperitoneal injection of either saline or EGF. Cytosolic (A, C) and
nuclear (B, D) extracts were prepared and immunocomplex kinase assays were used to assess p70S6k activities as described in Fig. 1. Results represent
means ± s.d.p70S6k activities increased several-fold in the normal tissues and
in the sarcomas and achieved approximately the same absolute
level (CE: sarcoma vs adjacent liver P = n.s.), (NE: sarcoma vs
adjacent liver P = n.s.), (CE: liver harbouring sarcoma vs control
liver P = n.s.), (NE: liver harbouring sarcoma vs control liver
P = n.s.).
p90rsk activities in hepatic tumours, livers harbouring
tumours and livers from control mice after
intraperitoneal injection of either saline or EGF
Immunocomplex kinase assays were carried out to assess the
activities of cytoplasmic and nuclear p90rsk (Figure 3) in the same
tissues used to measure MAPK (Figure 1) and p70S6k activities
(Figure 2).
Similar to the other two enzymes, p90rsk activities were higher
in the spontaneous and implanted tumours than in the adjacent
normal liver tissues or normal control livers (CE: adenoma vs
adjacent liver P < 0.05; carcinoma vs adjacent liver P < 0.05;
sarcoma vs adjacent liver P < 0.05), (NE: adenoma vs adjacent
liver P < 0.05; carcinoma vs adjacent liver P < 0.05; sarcoma vs
adjacent liver P < 0.05), (CE: adenoma vs control liver P < 0.01;
carcinoma vs control liver P < 0.01; sarcoma vs control liver
P < 0.05), (NE: adenoma vs control liver P < 0.05; carcinoma vs
control liver P < 0.01; sarcoma vs control liver P < 0.05). Similar
to the other two kinases, p90rsk activities in the adjacent liver
tissue were higher than in the livers in the normal animals, (CE:
liver harbouring adenoma vs control liver P < 0.05; liver
harbouring carcinoma vs control liver P < 0.05; liver harbouring
sarcoma vs control liver P < 0.05), (NE: liver harbouring
adenoma vs control liver P < 0.01; liver harbouring carcinoma vs
control liverP < 0.01; liver harbouring sarcoma vs control liver P
< 0.01). Also, as with MAPK and p70S6k, the EGF-induced
p90rsk activities reached approximately the same absolute level
in the liver of control animals, livers harbouring the tumours and
the tumours themselves. (CE: adenoma vs adjacent P = n.s.; carci-
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Figure 3 p90rsk activities in hepatic spontaneous tumours, livers harbouring tumours and livers from control CBA-T6/W mice (A, B) and in hepatic-implanted
sarcomas, livers harbouring tumours and livers from control BALB/c mice (C, D) after intraperitoneal injection of either saline or EGF. Cytosolic (A, C) and
nuclear (B, D) extracts were prepared and immunocomplex kinase assays were used to assess p90rsk activities as described in Figure 1. Results represent
means ± s.dnoma vs
adjacent  P < 0.05; sarcoma vs adjacent liver P = n.s.), (NE:
adenoma vs adjacent P = n.s.; carcinoma vs adjacent P < 0.05;
sarcoma vs adjacent liver P = n.s.), (CE: adenoma vs control liver
P = n.s.; carcinoma vs control liver P < 0.05; sarcoma vs control
liver P = n.s.), (NE: adenoma vs control liver P = n.s.; carcinoma
vs control liver P < 0.05; sarcoma vs control liver P = n.s.), (CE:
liver harbouring adenoma vs control liver P = n.s.; liver
harbouring carcinoma vs control liver P = n.s.; liver harbouring
sarcoma P = n.s.), (NE: liver harbouring adenoma vs control liver
P = n.s.; liver harbouring carcinoma vs control liver P = n.s.; liver
harbouring sarcoma vs control liver P = n.s.). However, compared
to the other two kinases, the profiles of p90rsk activities were
different in two important ways. First, in all tissues examined the
basal and EGF-inducible nuclear p90rsk activities were higher
than those measured in the cytoplasm. Second, in the CBA-T6/W
animals (Figure 3) the EGF-response of p90rsk was either small
or not demonstrable at all, particularly in the nuclear fractions.
In summary, these results show that the basal MAPK, p70S6k
and p90rsk activities are elevated in several hepatic tumours but in
most instances the basal activities were significantly below the
MAPK, p70S6k and p90rsk activities that were induced by
systemic administration of EGF. The basal, but not the EGF-
induced, activities of these enzymes appear to correlate with
histology of the tumour with the higher levels measured in the
carcinomas and sarcomas compared to adenomas. Unexpectedly,
the basal, but not the EGF-induced, MAPK, p70S6k and p90rsk
activities in normal tissue of livers harbouring these tumours were
greater than the activities measured in livers from control animals.
MAPK, p70S6k and p90rsk protein levels in hepatic
tumours and livers harbouring tumours and livers from
control mice
Immunoblot analyses of the same total amount of cytoplasmic and
nuclear protein extracts were carried out to determine whether the
increased kinase activities reflected changes in the kinase protein
levels. As shown in Figure 4, detectable levels of cytoplasmic and
nuclear MAPK, p70S6k and p90rsk were found, which did not
differ significantly between extracts from spontaneous tumours,
livers harbouring tumours and livers from control animals. Thus,
kinase activation of these enzymes in adenomas and adenocarci-
nomas and the adjacent liver tissue does not seem to reflect net
increase in kinase protein levels but rather may reflect protein
modification, most likely phosphorylation. Since the total amount
of proteins extracted from the cytoplasm is several-fold higher
than the total amount of protein extracted from the hepatic nuclei,
the total levels of these kinases is several-fold higher in the cyto-
plasm than in the nucleus. In contrast, Western blots revealed
MAPK, p70S6k and p90rsk in liver tumours 1047
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Figure 4 Immunoblotting of cytosolic and nuclear extracts from hepatic spontaneous tumours, implanted sarcomas, tumour harbouring livers and livers from
normal control animals (CBA-T6/W or sham-operated BALB/c mice). Equal amounts of protein (100 mg) were separated by SDS-PAGE, proteins were
transferred to PVDF membrane and probed with specific antibodies to MAPK, p70S6k and p90rsk. Results are from single experiments representative of at
least three experiments giving similar results. 1. normal liver from CBA-T6/W; 2. adenoma; 3. liver harbouring adenome; 4. cacinoma; 5. liver harbouring
carcinoma; 6. normal liver from BALB/C; 7. sarcoma; 8. liver harbouring sarcoma
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Figure 5 Identification of EGFR purified from hepatic spontaneous tumours,
implanted sarcomas and liver harbouring tumours. Equal amounts of
cytoplasmic protein (100 mg) were separated by SDS-PAGE, proteins were
transferred to PVDF membrane and probed with specific antibodies to EGFR.
Results are representative of at least three giving similar results. Figure 6 Tyrosine phosphorylation of EGFR purified from hepatic
spontaneous tumours, implanted sarcomas and tumour harbouring livers.
Equal amounts of cytoplasmic protein (1 mg) were immunoprecipitated with
anti-EGFR antibodies. Proteins, eluted from protein A/G by boiling in loading
buffer, were separated by SDS-PAGE, transferred to PVDF membrane, and
probed with either specific antibodies to EGFR (upper panel) or anti-
phosphotyrosine (anti-pTyr) (lower panel). Results are representative of three
experiments giving similar results.increased protein amounts of MAP, p70S6 and p90rs kinases in
cytoplasmic and nuclear extracts from implantable sarcomas
comparing to the extracts from both livers harbouring sarcomas
and livers from normal control animals.
EGF receptor levels in hepatic tumours and livers
harbouring tumours
EGFR protein levels in cell extracts from spontaneous hepatocel-
lular neoplasms, implanted L1 sarcoma tumours, and normal livers
adjacent to tumours were assessed by Western blotting analysis
using anti-EGFR antibodies. The results showed (Figure 5) that in
each pair of tumour and tumour-harbouring liver, the liver tissue
contained higher level of 170 kDa EGFR than that detected in the
corresponding neoplasms. These results, which are in agreement
with studies previously reported by Yang and co-workers (Yang
et al, 1994) in rats with transplantable tumours, suggest that the
EGFRs in liver neoplasms are down-regulated. An additional band
of lower molecular weight (approximately 150 kDa) was also
found in both tumours and adjacent livers; this band likely repre-
sents a proteolytic product of 170 kDa receptor (Yang et al, 1994).
Interestingly, proteolytic products of EGFR in both sarcomas and
sarcoma-harbouring liver have faster electrophoretic mobility than
those found in spontaneous tumours and the adjacent livers. In
contrast to differences in EGFR protein levels, the anti-phospho-
tyrosine blots revealed that the intensity of a 170 kDa band of
EGFR was similar in immunoprecipitated extracts from hepatic
tumours and the adjacent livers (Figure 6). The putative prote-
olytic product of the EGFR was not tyrosine-phosphorylated.
While these results demonstrate that the total number of phospho-
tyrosines present in EGFRs is similar in both tissues, the stoi-
chiometry of tyrosine phosphorylation in normal tissues might be
lower.
Constitutive activity of ODC is increased in the liver
tumours and in the normal liver tissue that harbours
these tumours
We next assessed the ODC activity in these tumours since this
enzyme is thought to play a role in the mitogenic responses. In old
CBA-T6 and young BALB/c mice ODC activity in livers from
normal animals averaged 29 ± 11 and 95 ± 28 pmol h–1 mg–1
protein respectively (Figure 7). ODC activity in spontaneous
neoplasms and implanted sarcomas were greater than the activity
of ODC in normal tissue of the livers bearing the tumours.
Compared to the normal tissue, the ODC activity in the tumours
was two- to eightfold higher, with the highest differences observed
between normal tissue and the implanted sarcomas. As in the case
of kinases, ODC activities in the normal tissue harbouring the
tumour was significantly higher than the activity measured in the
liver extracts from control mice (Figure 7).
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Figure 7 ODC activities in hepatic spontaneous tumours, livers harbouring tumours and livers from control CBA-T6/W mice (A) and in hepatic-implanted
sarcomas, livers harbouring tumours and livers from control BALB/c mice (B). ODC activities were measured using L-[14C]-ornithine hydrochloride as a substrate
in hepatocellular adenomas (n = 7), hepatocellular carcinomas (n = 4) and sarcomas implanted into liver (n = 10). For comparison, ODC activities were also
measured in normal livers harbouring tumours and in livers from control animals. Results represent means ± s.d.
Figure 8 Activation of AP-1 DNA-binding activity in liver tumours. AP-1
DNA-binding activity was assayed using electrophoretic mobility shift assay
in nuclear extracts derived from either hepatocellular adenoma,
hepatocellular carcinoma and sarcoma implanted into livers or the liver
around tumours.
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sarcoma
Free
probe
AP-1AP-1 DNA-binding activity is increased in hepatic
tumours but not in the livers that harbour these
tumours
AP-1 is a transcription factor that is involved in mitogenic
processes, including oncogenesis. AP-1 is activated by a number
of growth factors, including EGF. We have recently shown that
systemic administration of EGF activates AP-1 DNA-binding
activity in nuclei of mouse livers (Ostrowski et al, 2000). The
growth factor-triggered AP-1 activation is mediated by the MAP
kinase cascades. As is shown in Figure 8, AP-1 DNA-binding
activity is increased in nuclear extracts from the neoplasms, but
unlike the enzyme activities (Figures 1–3 and 7) the increased AP-
1 DNA-binding activity does not correlate with the tumours’
histology. Also, unlike the enzymes that we studied, no activation
of AP-1 DNA-binding activity was found in the nuclear extracts
derived from the normal tissue of the livers that had the tumours.
The nuclear levels of the individual members of the Fos (c-Fos,
FosB, Fra-1 and Fra-2) and Jun (c-Jun, JunB and JunD) family
were assessed by immunoblot analyses of nuclear extracts
prepared from hepatic neoplasms and tumour harbouring livers.
As shown in Figure 9, detectable levels of Fos and Jun nuclear
proteins were found in spontaneous and implanted hepatic tumours
as well as in adjacent normal livers. The nuclear protein concentra-
tion of c-Fos, FosB, Fra2, c-Jun and JunB were very similar in the
tumours and the tumour harbouring livers, whereas some
increased accumulation of Fral and JunD was found in normal
livers as compared to liver tumours.
DISCUSSION
This study shows that the activities of MAPK, p70S6k and p90rsk
are increased in hepatocellular neoplasms. We also demonstrated
elevated activity of ODC in these neoplasms. The enhanced
MAPK activity in hepatic tumours is consistent with similar obser-
vations made in human and rat colorectal cancers (Licato et al,
1997; Ostrowski et al, 1998), renal cell carcinoma (Oka et al,
1995), prostate cancer (Magi-Galluzzi et al, 1997), and a subset of
acute, but not chronic myelogenous leukaemias (Towatari et al,
1997). However, increased activities of p70S6k and p90rsk have
not been previously reported. To our knowledge this is also the
first demonstration that kinases and ODC activities are increased
in tissues surrounding tumours.
MAPK, p90rsk and p70S6k are normally activated by ligand
binding to the cell surface receptors (Lewis et al, 1998). In onco-
genic processes these kinases can also be activated by mutated
intracellular mediators that are constitutively driving these path-
ways. A well described example of such an oncogenic process is
mutated RAS (Santos et al, 1984). Since the signal transduction
pathways that activate MAPK and p70S6k are fundamentally
different, the observation that these kinases are concurrently acti-
vated suggests that the triggers for their activation in these tumours
are located at the earliest tiers of the signal transduction pathways.
In fact, it is conceivable that a trigger point is located at the level of
growth factor receptor itself where its activation might be ligand-
mediated. For example, the EGFR could be driven by EGF. Such a
possibility is consistent with our observation that there is a concur-
rent basal activation of MAPK, p90rsk and p70S6k in hepatic
tumours that is reminiscent of the profile of kinase activation by
EGF (Ostrowski et al, 2000) (Figures 1–3).
If the above postulate is correct, what is the source of EGF (or
another mitogen)? Malignant cells are able to synthesize several
cytokines and growth factors sometimes acting in an autocrine
stimulatory fashion, which – following extracellular release –
might function primarily as para/endocrine stimuli. It is therefore
conceivable that, in part, the activation of the MAPK, p90rsk and
p70S6k is mediated by EGF and/or other growth factors that are
secreted by the tumour. Two observations made in this study are
consistent with such a possibility:
1. MAPK, p90rsk and p70S6k activities were consistently higher
in the liver surrounding the tumours compared to livers from
control animals. Although there are other explanations, the
elevated MAPK, p90rsk and p70S6k activities may reflect
increased production of EGF, and/or other growth factors, by
hepatic tumours that reach other parts of the involved liver.
2. EGFR level was significantly lower in tumours compared to
liver harbouring tumour suggesting EGF-mediated receptor
down-regulation. Systemic administration of EGF stimulated
MAPK, p90rsk and p70S6k not only in normal livers but also
in the tumours. Regardless of histology, the EGF-induced
activities achieved approximately the same levels in all the
tissues examined. This means that the tumours are fully
responsive to EGF in a way similar to normal tissue.
If paracrine secretion by the tumours is responsible for the
elevation of kinase activities, then it is conceivable that EGF
and/or other mitogens could be contributing to the generation and
maintenance of these malignant processes. Even if paracrine secre-
tion of EGF does play a role, EGF is surely only one of many
factors contributing to these malignancies. The observation that
the liver surrounding the tumour was histologically normal yet it
had elevated kinase activities support the notion that activation of
these enzyme is not in a simple relation to hepatic malignancy. It is
conceivable that AP-1 along with other transcription factors are
key components responsible for the enhanced mitogenic state of
the tumours. It is conceivable that a given threshold of kinase
MAPK, p70S6k and p90rsk in liver tumours 1049
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Figure 9 Western blot analyses of AP-1 nuclear proteins in hepatic
spontaneous tumours, implanted sarcomas and tumour harbouring livers.
Nuclear extracts (100 mg) were fractionated by SDS-PAGE and transferred to
PVDF membranes. Immunoblots were performed with antibodies specific for
c-Fos, FosB, Fra-1, Fra-2, c-Jun, JunB and JunD. Results are from single
experiments representative of at least three experiments giving similar results
1. adenoma; 2. liver harbouring adenoma; 3. carcinoma; 4. liver harbouring
carcinoma; 5. sarcoma; 6. liver harbouring sarcoma.activities is required to trigger AP-1, which (in conjunction with
many other factors) induces the oncogenic process.
In summary, our study demonstrates a significant basal activa-
tion of MAP, p90rs and p70S6 kinases and high constitutive AP-1
DNA binding activity in mouse spontaneous hepatic adenomas
and carcinomas. The activities of kinases, but not that of AP-1,
were also increased in surrounding liver tissue. Unlike the
different basal activities, the EGF-triggered kinase responses in
normal liver and liver tumours were indistinguishable. These
observations open up a new avenue to explore the intracellular
mechanisms responsible for the generation and maintenance of
hepatic tumours.
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